Duality Advisers LP boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 56.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,763 shares of the biopharmaceutical company’s stock after buying an additional 9,619 shares during the quarter. Duality Advisers LP’s holdings in Amicus Therapeutics were worth $380,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Amicus Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 27,131,873 shares of the biopharmaceutical company’s stock valued at $329,924,000 after purchasing an additional 107,456 shares during the period. William Blair Investment Management LLC boosted its stake in shares of Amicus Therapeutics by 349.9% during the third quarter. William Blair Investment Management LLC now owns 10,376,763 shares of the biopharmaceutical company’s stock valued at $126,181,000 after purchasing an additional 8,070,098 shares during the period. Fiera Capital Corp boosted its stake in shares of Amicus Therapeutics by 2.1% during the third quarter. Fiera Capital Corp now owns 5,085,871 shares of the biopharmaceutical company’s stock valued at $61,844,000 after purchasing an additional 106,086 shares during the period. American Century Companies Inc. boosted its stake in shares of Amicus Therapeutics by 11.0% during the third quarter. American Century Companies Inc. now owns 4,343,870 shares of the biopharmaceutical company’s stock valued at $52,821,000 after purchasing an additional 429,257 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in Amicus Therapeutics by 392.4% in the third quarter. Victory Capital Management Inc. now owns 2,949,206 shares of the biopharmaceutical company’s stock worth $35,862,000 after acquiring an additional 2,350,262 shares during the period.
Amicus Therapeutics Stock Performance
FOLD opened at $10.17 on Friday. Amicus Therapeutics, Inc. has a 52-week low of $9.70 and a 52-week high of $14.57. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.52 and a current ratio of 2.88. The firm’s 50-day moving average price is $12.02 and its 200-day moving average price is $12.00.
Insider Activity
In other news, insider David Michael Clark sold 4,427 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $61,978.00. Following the transaction, the insider now owns 253,664 shares in the company, valued at $3,551,296. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider David Michael Clark sold 4,427 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total value of $61,978.00. Following the sale, the insider now owns 253,664 shares in the company, valued at $3,551,296. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bradley L. Campbell sold 4,167 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $58,338.00. Following the completion of the sale, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The disclosure for this sale can be found here. Insiders have sold a total of 48,108 shares of company stock worth $662,605 over the last 90 days. 2.10% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
A number of research firms recently weighed in on FOLD. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, February 29th. JPMorgan Chase & Co. reduced their target price on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, March 18th.
Check Out Our Latest Stock Analysis on FOLD
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
See Also
- Five stocks we like better than Amicus Therapeutics
- Stock Sentiment Analysis: How it Works
- Hasbro’s Management Made All the Right Calls This Quarter
- Which Wall Street Analysts are the Most Accurate?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- With Risk Tolerance, One Size Does Not Fit All
- Power Surge: Utilities Sector’s Resilience Shines
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.